Drug evaluation: Sapacitabine - An orally available antimetabolite in the treatment of cancer

Current Opinion in Investigational Drugs

Volumn 7, Issue 6, 2006, Pages 565-573

  Galmarini, Carlos M ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CYANO 2 DEOXY BETA DEXTRO ARABINOPENTOFURANOSYL)CYTOSINE; 2' CYANO 2' DEOXY 4 N PALMITOYLCYTARABINE; ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; CYC 682; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; DEOXYCYTIDINE; DOXIFLURIDINE; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; PRODRUG; PYRIMIDINE NUCLEOSIDE DERIVATIVE; ROSCOVITINE; SAPACITABINE; UNCLASSIFIED DRUG; VINCRISTINE;

ANOREXIA; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DIAPHORESIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; MAXIMUM TOLERATED DOSE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PRURITUS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I; CYTOSINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; PATENTS;

EID: 33745147247     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. 4-palmitoylcytosine (CS-682). Kaneko M, Koga R, Murayama K, Shibata T, Hotoda H, Suzuki M PROC AM ASSOC CANCER RES 1997 38 88 101
2. 269969 Antitumor activity of a novel nucleoside 1-(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl)-N-4- palmitoylcytosine (CS-682). Fujita F, Fujita M, Sakamoto Y, Tsukagoshi S, Nomura T, Tsuruo T, Suzuki M, Hanaoka K, Mitsuhashi V, Kurakata S, Kobayashi T, Matsuda A, Sasaki T PROC AM ASSOC CANCER RES 1997 38 101-102
3. 269970 A novel mechanism of action of a new antitumor nucleoside, 1-(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl)-N-4- palmitoylcytosine (CS-682). Hanaoka K, Azuma A, Mitsuhashi Y, Kobayashi T, Kurakata S, Iwabuchi H, Sasaki T, Matsuda A, Tsuruo T PROC AM ASSOC CANCER RES 1997 38 88 101
4. 327218 A phase I study of the oral antimetabolite CS-682 in patients with refractory solid tumors. Dees EC, Summerson L, Carducci M, Grochow L, Kobayasji T, Kurakata S, Donehower RC PROC AM SOC CLIN ONCOL 1999 18 Abs 800
5. 369646 A phase I study of CS-682, an oral antimetabolite, in patients with refractory solid tumors. Donehower RC, Dees EC, Baker SD, Summerson L, Carducci MA, Izumi T, Kobayashi T PROC AM SOC CLIN ONCOL 2000 19 Abs 764
6. 391144 A phase I study of CS-682, an oral antimetabolite, in patients with refractory solid tumors. Gilbert J, Dees E, Baker S, Summerson L, Carducci M, Izumi T, Kobayashi T, Donehower R NCI EORTC SYMP NEW DRUGS CANCER THER 2000 11 Abs 443
7. 404452 Preclinical antitumor and antimetastatic efficacies of CS-682, a nucleoside analog with now mechanism of self-breakage of DNA strand. Wu M, Mazurchuk R, Pera P, Veith J, Chaudhary N, Grow W, Bernacki R, Hoffman R, Kobayasi T PROC AM ASSOC CANCER RES 2001 42 Abs 2915
8. 409952 Phase I study of orally administered CS-682 in solid tumors. Burch PA, Camoriano JK, Braich TA, Atherton PJ, Miyoshi K, Kobayashi T, Rubin J, Erlichman C PROC AM SOC CLIN ONCOL 2001 20 Pt 1 Abs 364
9. 445376 Anti-metastatic efficacy of CS-682 (1-(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine) in orthotopic models demonstrated by high resolution magnetic resonance imaging. Chaudhary ND, Wu M, Mazurchuk R, Spernyak J, Veith J, Pera P, Greco W, Hoffman RM, Kobayashi T, Bernacki RJ PROC AM ASSOC CANCER RES 2002 43 Abs 303
10. 457740 Nucleoside analogs: Mechanisms of drug resistance and reversal strategies. Galmarini CM, Mackey J, Dumontet C LEUKEMIA 2001 15 875-890
11. 477248 R&D pipeline. Sankyo Co Ltd COMPANY WORLD WIDE WEBSITE 2002 May 31
12. 516259 Cyclacel licenses anticancer drug from Sankyo. Cyclacel Ltd PRESS RELEASE 2003 December 05
13. 530789 Cytosine analog CS-682 is effective adjuvant therapy in orthotopic models of aggressive human pancreatic cancer. Katz MH, Takimoto S, Moossa AR, Bouvet M, Hoffman RM PROC AM ASSOC CANCER RES 2004 45 Abs 3045
14. 543662 Survival efficacy of adjuvant cytosine-analog CS-682 in a fluorescent orthotopic model of human pancreatic cancer. Katz M PROC AM SOC CLIN ONCOL 2004 23 Abs 2077
15. 543714 Nucleoside analogs and nucleobases in cancer treatment Galmarini CM, Mackey J, Dumontet C LANCET ONCOL 2002 3 415-424
16. 557959 Cyclacel initiates patient enrolment in third phase I clinical trial of CYC682. Cyclacel Ltd PRESS RELEASE 2004 September 07
17. 603172 Phase I and pharmacokinetic trial of oral administration of CYC682, a novel 2′-deoxycytidine type anti-metabolite pro-drug, in patients with advanced solid tumors or lymphoma. Tolcher A, Cohen RB, Benettaib B, Frenz L, Gianella-Borradori A, Calvo E PROC AM SOC CLIN ONCOL 2005 24 Abs 2026
18. 608635 Survival efficacy of adjuvant cytosine-analog CS-682 in a fluorescent orthotopic model of human pancreatic cancer. Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM CANCER RES 2004 64 5 1828-1833
19. 608637 Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer. Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM CANCER RES 2003 63 17 5521-5525
20. 4-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model. Wu M, Mazurchuk R, Chaudhary ND, Spernyak J, Veith J, Pera P, Greco W, Hoffman RM, Kobayashi T, Bernacki RJ CANCER RES 2003 63 10 2477-2482
21. 608644 Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682). Hanaoka K, Suzuki M, Kobayashi T, Tanzawa F, Tanaka K, Shibayama T, Miura S, Ikeda T, Iwabuchi H, Nakagawa A, Mitsuhashi Y, Hisaoka M, Kaneko M, Tomida A, Wataya Y, Nomura T, Sasaki T, Matsuda A, Tsuruo T, Kurakata S INT J CANCER 1999 82 2 226-236
22. 628541 Nucleosides and nucleotides. 122. 2′-C-cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum. Azuma A, Nakajima Y, Nishizono N, Minakawa N, Suzuki M, Hanaoka K, Kobayashi T, Tanaka M, Sasaki T, Matsuda A J MED CHEM 1993 36 26 4183-4189
23. 628543 Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2′-C-cyano- 2′-deoxy-1-β-D-arabino- pentofuranosylcytosine in alkaline medium: formation of 2′-C-cyano- 2′-deoxy-1-β-D-ribo- pentofuranosylcytosine and its antitumor activity. Azuma A, Hanaoka K, Kurihara A, Kobayashi T, Miyauchi S, Kamo N, Tanaka M, Sasaki T, Matsuda A J MED CHEM 1995 38 17 3391-3397
24. 2 arrest. Azuma A, Huang P, Matsuda A, Plunkett W MOL PHARMACOL 2001 59 4 725-731
25. 628545 Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1- β-D-arabino-pentofuranosylcytosine (CNDAC). Azuma A, Huang P, Matsuda A, Plunkett W BIOCHEM PHARMACOL 2001 61 1497-1507
26. 628547 Nucleoside transporters: molecular biology and implications for therapeutic development. Baldwin SA, Mackey JR, Cass CE, Young JD MOL MED TODAY 1999 5 5 216-224
27. 628550 Problems related to resistance to cytarabine in acute myeloid leukaemia. Cros E, Jordheim L, Dumontet C, Galmarini CM LEUK LYMPHOMA 2004 46 1123-1132
28. 628554 Substrate cycles and drug resistance to 1-β-D-arabinofuranosylcytosine (araC). Fernandez-Calotti P, Jordheim LP, Giordano M, Dumontet C, Galmarini CM LEUK LYMPHOMA 2005 46 3 335-346
29. 628559 Pyrimidine nucleoside analogs in cancer treatment Galmarini CM, Jordheim L, Dumontet C EXP REV ANTICANCER THER 2003 3 717-728
30. 628560 Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogs. Jordheim LP, Galmarini CM, Dumontet C BULL CANCER 2005 92 3 239-248
31. 628561 Design of a new antitumor nucleoside CNDAC, against solid tumors. Matsuda A GAN TO KAGAKU RYOHO 1996 23 2 202-210
32. 628562 Antitumor activity of sugar-modified cytosine nucleosides. Matsuda A, Sasaki T CANCER SCI 2004 95 2 105-111
33. 628565 Development and biochemical characterization of a 2′-C-cyano-2′-deoxy-1- β-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080. Obata T, Endo Y, Tanaka M, Matsuda A, Sasaki T CANCER LETT 1998 123 1 53-61
34. 628566 Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides. Obata T, Endo Y, Tanaka M, Uchida H, Matsuda A, Sasaki T JPN J CANCER RES 2001 92 7 793-798
35. 628567 Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Owens JK, Shewach DS, Ullman B, Mitchell BS CANCER RES 1992 52 9 2389-2393
36. 628569 Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine. Pereira S, Fernandes PA, Ramos MJ J COMPUT CHEM 2004 25 10 1286-1294
37. 628570 Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ CANCER RES 1994 54 15 4138-4143
38. 628571 Antitumor activity of a novel nucleoside, 2′-C-cyano-2′-deoxy-1-β-D-arabinofuranasylcytosine (CNDAC) against murine and human tumors. Tanaka M, Matsuda A, Terao T, Sasaki T CANCER LETT 1992 64 1 67-74
39. 628573 Isolation of deoxycytidine kinase from Ehrlich carcinoma cells by affinity chromatography based on a substrate analog, 2′-C-cyano-2′-deoxy-1- β-D-arabinofuranosyl-N4-palmitoylcytosine. Uchida H, Chen YX, Morinaga H, Hayashi Y, Matsuda A, Obata T, Endo Y, Sasaki T BIOL PHARM BULL 1999 22 1 83-86
40. 628574 Determinants in chemosensitivity of oncogene-transformed NIH3T3 cells to 2′-C-cyano-2′-deoxy-1- β-D-arabinofuranosylcytosine. Zhang M, Endo Y, Sasaki T INT J ONCOL 1999 14 3 543-549
41. 628575 2′-C-Cyano-2′-deoxy-1- β-D-arabinofuranosylcytosine (CNDAC): A mechanism-based DNA-strand-breaking antitumor nucleoside. Matsuda A, Azuma A NUCLEOSIDES NUCLEOTIDES 1995 14 461-471
42. 658451 Cyclacel Pharmaceuticals established with completion of Cyclacel Group plc and Xcyte Therapies Transactions. Cyclacel Ltd PRESS RELEASE 2006 March 28
43. 2 arrest induced by 2′-C-cyano-2′-deoxy-1- β-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Liu X, Guo Y, Li Y, Jiang Y, Chubb S, Azuma A, Huang P, Matsuda A, Hittelman W, Plunkett W CANCER RES 2005 65 15 6874-6881